The U.K.'s National Institute for Health and Clinical Excellence (NICE) this weekend issued a draft guidance stating that it does not recommend omalizumab, an...
The U.S. Food and Drug Administration this week approved Xeljanz (tofacitinib) for the treatment of moderate to severe rheumatoid arthritis (RA) in adults who have not responded to...
New trials show that a cancer drug can be an effective treatment for multiple sclerosis (MS) by 'rebooting' patients' immune systems. The results of two phase III clinical trials...
Isis Pharmaceuticals recently announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) found the company's drug, Kyna...
Today the Cellceutix Corporation announced that its new anti-cancer drug candidate Kevetrin will soon be entering clinical trials at the Harvard Cancer Center's Dana-Farber Cancer...
This week, ArQule, a biotechnology company focused on developing "next-generation" small-molecule cancer drugs, announced that a drug trial for a lung cancer treatment it developed...
The U.S. Food and Drug Administration (FDA) this week announced that it has approved a new drug for the treatment of colorectal cancer. According to the U.S. Centers for Disease C...
Two phase 3 clinical trials have shown that oral doses of a drug called BG-12 show "significant" and "clinically meaningful" reductions in multiple sclerosis (MS) relapses and brai...
The U.S. FDA this week approved a once-a-day pill for the treatment of multiple sclerosis (MS). The pill, being branded as "Aubagio" by Sanofi S.A., is specifically for the treatm...
Pfizer this week announced that Bosulif, a medication it developed for the treatment of a rare type of Leukemia, has been approved by the U.S. Food and Drug Administration.
The...
Gilead Sciences, a biotech research company, announced today that its new HIV treatment drug has been approved by the U.S. Food and Drug Administration. Dubbed Stribild, the once-...
GlaxoSmithKline (GSK) this week announced that phase III of trials for its new long-acting muscarinic antagonist/long-acting beta2 agonist (LAMA/LABA) drug are complete. The drug,...
Americans looking for medical advice are visiting medical websites, social media sites, and online communities in greater numbers than the websites of pharmaceutical companies,...
WebProNews is an iEntry Publication
